Posted by Michael Wonder on 28 Apr 2022
Access criteria for antiviral treatments widened as molnupiravir arrives in New Zealand
28 April 2022 - PHARMAC is widening access to the antivirals to treat people with early COVID-19, after receiving feedback from our expert advisors and clinicians that the access criteria needed updating and to be streamlined.
This comes in time for the arrival of the first shipment of MSD’s molnupiravir, giving vulnerable New Zealanders with COVID-19 access to three antiviral treatments.
